ArticleRheumatology (Oxford, England)2026
IFN-related gene expression defines disease activity, organ involvement and treatment response in JDM.
Article in Rheumatology (Oxford, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo evaluate the relationship between IFN-related gene (IRG) expression and disease activity, organ involvement and serological subgroups in JDM and to assess its potential as a biomarker for disease monitoring and treatment response.
methodsPatients with JDM enrolled in a single-centre cohort were assessed using standardized clinical measures, including physician's global assessment (PGA), Childhood Myositis Assessment Scale (CMAS), Manual Muscle Testing (MMT8) and modified skin disease activity score. Associations between IRG expression and clinical features were analysed using correlation analyses and mixed-effects models. Longitudinal trajectories of disease activity were explored using latent class mixed models.
resultsSeventy-four patients contributed 158 samples. Expression of type-I IRGs (IFI27, IFI44L, IFIT1, RSAD2, SIGLEC1) and CXCL10 was significantly higher in active disease and correlated with muscle and skin disease activity. IRG expression inversely correlated with CMAS and MMT8 and positively with mDAS. Distinct organ-specific associations were identified: CXCL9 expression was associated with interstitial lung disease, while IL-18 was associated with calcinosis, cutaneous ulceration and gastrointestinal involvement. Higher IRG expression was observed in patients with anti-MDA5 and anti-NXP2 autoantibodies. Longitudinal analyses demonstrated that IRG expression paralleled disease activity trajectories and decreased in patients achieving inactive disease, including those treated with baricitinib.
conclusionIFN pathway activation is closely associated with disease activity and organ involvement in JDM. IRG expression reflects dynamic changes in disease status and may serve as a clinically useful biomarker for monitoring disease activity, stratifying patients by organ involvement and supporting response assessment to targeted therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.